Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKACA | P17612 | 3/20 | 0.47 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.47 |
| ▸ | GSK3B | P49841 | 3/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.44 |
| ▸ | OGFRL1 | Q5TC84 | 8/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 6/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21311242 | 1.00 | PRKACA (0.47) | PRKACARPS6KB1GSK3BROCK1TP53 | |
| SCHEMBL21311265 | 1.00 | PRKACA (0.47) | PRKACARPS6KB1GSK3BROCK1TP53 | |
| SCHEMBL21311262 | 1.00 | PRKACA (0.47) | PRKACARPS6KB1GSK3BROCK1TP53 | |
| SCHEMBL21310921 | 0.92 | RPS6KB1 (0.45) | PRKACARPS6KB1GSK3BROCK1TP53 | |
| SCHEMBL21310918 | 0.92 | RPS6KB1 (0.45) | PRKACARPS6KB1GSK3BROCK1TP53 | |
| SCHEMBL6196431 | 0.87 | RPS6KB1 (0.58) | PRKACARPS6KB1GSK3BROCK1TP53 | |
| SCHEMBL21148134 | 0.87 | RPS6KB1 (0.58) | PRKACARPS6KB1GSK3BROCK1TP53 | |
| SCHEMBL6196424 | 0.87 | RPS6KB1 (0.58) | PRKACARPS6KB1GSK3BROCK1TP53 | |
| SCHEMBL6198016 | 0.87 | RPS6KB1 (0.58) | PRKACARPS6KB1GSK3BROCK1TP53 | |
| SCHEMBL22725453 | 0.85 | NOS2 (0.46) | PRKACARPS6KB1GSK3BROCK1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11174245-B2 | Benzimidazole compounds and derivatives as EGFR inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-11-16 | — | — | US | disclosed |
| US-20200377476-A1 | NEW BENZIMIDAZOLE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-12-03 | — | — | US | disclosed |
| WO-2019162323-A1 | NEW BENZIMIDAZOLE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377476-A1 | NEW BENZIMIDAZOLE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | PRKACA 361/4885RPS6KB1 357/4885GSK3B 583/4885 |
| US-11174245-B2 | Benzimidazole compounds and derivatives as EGFR inhibitors | EGFR, ERBB2, ERBB3 | PRKACA 353/4885RPS6KB1 412/4885GSK3B 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.